Phase-IIa Study of AJM300 in Patients with Active Ulcerative Colitis
Phase 2
- Conditions
- lcerative Colitis
- Registration Number
- JPRN-jRCT2080222244
- Lead Sponsor
- Ajinomoto Pharmaceuticals Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with active-phase ulcerative colitis
- The Mayo score of 6 to 10.
- Mucosal appearance subscore of 2 or more, and Rectal bleeding subscore of 1 or more
- Inadequate response to or intolerance of appropriate conventional therapy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mayo score, Safety
- Secondary Outcome Measures
Name Time Method